MedTrace Logo

A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

NCT01062958 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2013-04-16

No results posted yet for this study

Summary

This study is a multi-site, retrospective chart review to determine the effect of Neevo® or Neevo®DHA (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the course of pregnancy. Neevo® is a prescription medical food indicated for the dietary management of women under a doctor's care who face high risk pregnancies, older overactive bladder (OB) patients and patients unable to fully metabolize folic acid. Data will be collected from existing patient charts of subjects administered Neevo® or Neevo®DHA daily compared to subjects administered a prenatal vitamin daily.

Conditions

Interventions

OTHER

Neevo® (a medical food)

OTHER

Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)

Sponsors & Collaborators

  • Baylor Health Care System

    collaborator OTHER

  • Women's Clinic Shoals

    collaborator UNKNOWN

  • Gainesville Obstetrics & Gynecology

    collaborator OTHER

  • Womens Health Associates

    collaborator UNKNOWN

  • Pamlab, Inc.

    lead INDUSTRY

Principal Investigators

  • Susan Bentley, CRNP · Women's Clinic Shoals

Eligibility

Min Age
21 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062958 on ClinicalTrials.gov